Specific PAH drugs, including ERAs, PDE5, Riociguat, prostacyclin receptor agonists such as Selexipag, and prostanoids, have been studied in a small number of patients, and there is a lack of data supporting their use in haemolytic anaemia patients [14]. Here, PDE5A is linked to non-autoimmune hemolytic anemia.